Bookbuilding IPO | ₹582 Cr | Listed at BSE, NSE | Fri, Dec 20, 2024 - Tue, Dec 24, 2024
Senores Pharmaceuticals IPO is a book build issue of ₹582.11 crores. The issue is a combination of fresh issue of 1.28 crore shares aggregating to ₹500.00 crores and offer for sale of 0.21 crore shares aggregating to ₹82.11 crores.
Senores Pharmaceuticals IPO bidding started from Dec 20, 2024 and ended on Dec 24, 2024. The allotment for Senores Pharmaceuticals IPO was finalized on Dec 26, 2024. The shares got listed on BSE, NSE on Dec 30, 2024.
Senores Pharmaceuticals IPO price band is set at ₹391 per share. The lot size for an application is 38. The minimum amount of investment required by an retail is ₹14,858 (38 shares) (based on upper price). The lot size investment for sNII is 14 lots (532 shares), amounting to ₹2,08,012, and for bNII, it is 68 lots (2,584 shares), amounting to ₹10,10,344.
The issue includes a reservation of up to 75,000 shares for employees offered at a discount of ₹0.00 to the issue price.
Equirus Capital Pvt.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Senores Pharmaceuticals IPO RHP for detailed Information.
IPO Open
Fri, Dec 20, 2024
IPO Close
Tue, Dec 24, 2024
Issue Price
₹391 per share
Market Cap (Pre-IPO)
₹1,350.70 Cr
| IPO Date | 20 to 24 Dec, 2024 |
| Listed on | Mon, Dec 30, 2024 |
| Face Value | ₹10 per share |
| Price Band | ₹372 to ₹391 |
| Issue Price | ₹391 per share |
| Lot Size | 38 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 1,48,87,723 shares (agg. up to ₹582 Cr) |
| Fresh Issue | 1,27,87,723 shares (agg. up to ₹500 Cr) |
| Offer for Sale | 21,00,000 shares of ₹10 (agg. up to ₹82 Cr) |
| Share Holding Pre Issue | 3,32,65,865 shares |
| Share Holding Post Issue | 4,60,53,588 shares |
| BSE Script Code / NSE Symbol | 544319 / SENORES |
| ISIN | INE0RB801010 |
Senores Pharmaceuticals IPO offers total 1,48,87,723 shares. Out of which 1,11,09,543 (74.62%) allocated to QIB, 44,43,818 (29.85%) allocated to QIB (Ex- Anchor), 22,21,908 (14.92%) allocated to NII 14,81,272 (9.95%) allocated to RII and 66,65,725 (44.77%) allocated to Anchor investors.
| Investor Category | Shares Offered | Max Allottees |
|---|---|---|
| QIB Shares Offered | 1,11,09,543 (74.62%) | NA |
| − Anchor Investor Shares Offered | 66,65,725 (44.77%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 44,43,818 (29.85%) | NA |
| NII (HNI) Shares Offered | 22,21,908 (14.92%) | NA |
| − bNII > ₹10L | 14,81,272 (9.95%) | 2,784 |
| − sNII < ₹10L | 7,40,636 (4.97%) | 1,392 |
| Retail Shares Offered | 14,81,272 (9.95%) | 38,980 |
| Employee Shares Offered | 75,000 (0.50%) | NA |
| Total Shares Offered | 1,48,87,723 (100.00%) |
Investors can bid for a minimum of 38 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 38 | ₹14,858 |
| Retail (Max) | 13 | 494 | ₹1,93,154 |
| S-HNI (Min) | 14 | 532 | ₹2,08,012 |
| S-HNI (Max) | 67 | 2,546 | ₹9,95,486 |
| B-HNI (Min) | 68 | 2,584 | ₹10,10,344 |
Senores Pharmaceuticals IPO raises ₹260.63 crore from anchor investors. Senores Pharmaceuticals IPO Anchor bid date is December 19, 2024.
📝 Anchor Investors Letter (PDF)
| Bid Date | Thu, Dec 19, 2024 |
| Shares Offered | 66,65,725 |
| Anchor Portion (₹ Cr.) | 260.63 |
| Anchor lock-in period end date for 50% shares (30 Days) | Fri, Jan 24, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | Tue, Mar 25, 2025 |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Up to Rs 2 Lakhs | Yes |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Incorporated in December 2017, Senores Pharmaceuticals Limited develops and manufactures a range of pharmaceutical products primarily for the regulated markets of the US, Canada, and the UK, while also serving emerging markets.
The company's product portfolio consists of Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Capsules, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets Topiramate Capsules, and Ivermectin Tablets for regulated markets.
As of September 30, 2024, the company has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments. They have established partnerships with distributors and hospitals across several states in India.
As of September 30, 2024, the company operates three dedicated R&D facilities in India and the US.
The company operates in Emerging Markets across 43 countries and manufactures critical care injectables and APIs.
The company's manufacturing unit is situated in Ahmedabad, Gujrat.
Competitive Strength
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 678.08 | 621.88 | 131.05 | 59.15 |
| Total Income | 183.35 | 217.34 | 39.02 | 14.63 |
| Profit After Tax | 23.94 | 32.71 | 8.43 | 0.99 |
| NET Worth | 319.06 | 231.71 | 45.50 | 36.59 |
| Reserves and Surplus | 263.36 | 175.94 | 35.25 | 25.37 |
| Total Borrowing | 242.03 | 248.38 | 60.76 | 14.21 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Investment in one of the Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility | 107.00 |
| 2 | Re-payment/pre-payment, in full or in part, of certain borrowings availed by the Company | 73.48 |
| 3 | Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries | 20.22 |
| 4 | Funding the working capital requirements of the Company | 43.26 |
| 5 | Investment in the Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements | 59.48 |
| 6 | Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes | 154.37 |
| KPI | Mar 31, 2024 |
|---|---|
| ROE | 23.60% |
| ROCE | 11.73% |
| Debt/Equity | 1.07 |
| RoNW | 23.60% |
| PAT Margin | 15.25% |
| Price to Book Value | 5.84 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 9.83 | 13.86 |
| P/E (x) | 39.77 | 28.21 |
| Promoter Holding | 66.67% | 45.77% |
| Market Cap | ₹1,350.70 Cr. |
The Senores Pharmaceuticals IPO is subscribed 97.86 times on December 24, 2024 6:19:11 PM (Day 3). The public issue subscribed 93.16 times in the retail category, 97.84 times in the QIB category, and 100.35 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB | 97.84 | 44,43,817 | 43,47,78,102 |
| NII | 100.35 | 22,21,909 | 22,29,63,632 |
| bNII (bids above ₹10L) | 95.25 | 15,18,605 | 14,46,53,764 |
| sNII (bids below ₹10L) | 111.35 | 7,03,304 | 7,83,09,868 |
| Retail | 93.16 | 14,81,272 | 13,79,96,126 |
| Total | 97.86 | 81,46,998 | 79,72,31,982 |
Total Application : 37,01,011
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Fees payable to the BRLMs | 22.32 |
| 2 | Brokerage, selling commission, upload fees, processing fees and bidding charges for the Members of the Syndicate, Registered Brokers, SCSBs, RTAs and CDPs | 3.03 |
| 3 | Fees payable to legal counsel, chartered accountants, and other intermediaries | 4.67 |
| 4 | Listing fees, SEBI filing fees, book building software fees, depository charges and other regulatory expenses | 5.79 |
| 5 | Printing and despatch of issue stationery expenses | 1.68 |
| 6 | Advertising and marketing expenses for the Issue; and | 3.90 |
| 7 | Miscellaneous | 0.80 |
| Price Details | BSE |
|---|---|
| Final Issue Price | ₹391.00 |
| Open | ₹593.70 |
| Low | ₹538.85 |
| High | ₹609.00 |
| Last Trade | ₹557.80 |
Lead Manager Reports
Senores Pharmaceuticals IPO is a main-board IPO of 1,48,87,723 equity shares of the face value of ₹10 aggregating up to ₹582 Crores. The issue is priced at ₹391 per share. The minimum order quantity is 38.
The IPO opens on Fri, Dec 20, 2024, and closes on Tue, Dec 24, 2024.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Senores Pharmaceuticals IPO using UPI as a payment gateway. Zerodha customers can apply in Senores Pharmaceuticals IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Senores Pharmaceuticals IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Senores Pharmaceuticals IPO opens on Fri, Dec 20, 2024 and closes on Tue, Dec 24, 2024.
Senores Pharmaceuticals IPO lot size is 38, and the minimum amount required for application is ₹14,858.
You can apply in Senores Pharmaceuticals IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Senores Pharmaceuticals IPO will be done on Thursday, December 26, 2024, and the allotted shares will be credited to your demat account by Fri, Dec 27, 2024. Check the Senores Pharmaceuticals IPO allotment status.
The Senores Pharmaceuticals IPO listing date is on Mon, Dec 30, 2024.
